MPM BioImpact Announces Promotion of Rami Rahal, Ph.D., to Partner

MPM BioImpact, a biotechnology investment firm creating and investing in innovative companies seeking to deliver transformative therapies to patients, today announced the promotion of Rami Rahal, Ph.D., to Partner.

"We are proud to announce Rami’s well-deserved promotion in recognition of the tremendous value he has brought to the public investing team at MPM BioImpact,” said Christiana Bardon, M.D., Managing Partner of MPM BioImpact. “Our goal is to invest in companies whose drugs will go on to transform patient outcomes. Rami’s experience as a scientist and drug developer has been instrumental in expanding our diligence framework and providing critical insights during our investment process. He has proven to be a trusted partner to our public investment team, as well as an important advisor across our broader portfolio.”

As Partner, Rami will continue working with Christiana Bardon, M.D., Managing Partner of MPM BioImpact and Portfolio Manager of the BioImpact Equities (BIE) funds, as well as the rest of the MPM BioImpact team, to invest in public biotechnology companies.

“Rami’s scientific judgment is outstanding. His ability to distill complex biology, coupled with his expertise in drug discovery, has allowed us to identify and invest in the next generation of transformative medicines in our industry. Through our private and public portfolios, MPM BioImpact invests across the entire spectrum of biotechnology, enabling us to see almost every new technology, asset, and company in the industry,” said Ansbert Gadicke, M.D., Managing Partner of MPM BioImpact.

Prior to joining MPM BioImpact in 2022, Rami spent the majority of his career advancing precision oncology and immunotherapy medicines, including Gavreto, an FDA approved therapy for RET-driven metastatic non-small cell lung cancer (NSCLC) and advanced thyroid cancers. Rami previously held roles at Scorpion Therapeutics, Blueprint Medicines, and KSQ Therapeutics. Rami originally trained as a geneticist at Massachusetts Institute of Technology and conducted postdoctoral fellowships at Harvard Medical School and the Novartis Institutes for Biomedical Research.

Rami commented, “the transition from a drug hunter to a public investor was not an easy one, but it has been one of the most rewarding experiences in my career. It is a drug developer’s dream to follow the entire universe of innovative medicines developing in real time. Ansbert and Chris have assembled an incredible team, including some of the most experienced and thoughtful drug developers I’ve ever worked with, and I look forward to continuing to learn from them for years to come.”

About MPM BioImpact

MPM BioImpact is a world-leading biotechnology investment firm with over 30 years of expertise creating and investing in innovative companies to deliver transformative therapies to patients. Its experienced and dedicated team of investment professionals, entrepreneurs, advisors and leading scientists translate scientific discoveries into breakthrough medicines and potential cures. The Firm manages over $3.5 billion AUM across early-stage venture funds, private/public impact funds and public equities funds. For more information, visit www.mpmbioimpact.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250108969291/en/